Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
Novavax (NASDAQ: NVAX) is facing some significant headwinds. Its financials aren't in great shape, and its future remains questionable. Investors have been dumping the stock in droves, and it is no longer near the highs it reached toward the start of the year. But with the stock trading at a deep discount to its rivals, has it become so cheap that it's worth taking a chance on Novavax?
Novavax trades at a price-to-sales multiple of well below 1. It's remarkably cheap when compared to fellow COVID-19 vaccine makers Pfizer and Moderna.
Source Fool.com
Novavax Inc. Stock
Based on 3 Buy predictions and 2 Sell predictions the sentiment towards Novavax Inc. is rather balanced.
With a target price of 12 € there is potential for a 215.08% increase which would mean more than doubling the current price of 3.81 € for Novavax Inc..